Return to Current Article

Kythera Newsroom

KYTHERA Biopharmaceuticals To Participate In The Private Company Forum At The 28th Annual Goldman Sachs Global Healthcare Conference

June 5, 2007

LOS ANGELES, June 5, 2007  – Kythera Biopharmaceuticals, Inc. ("Kythera") announced today its participation in the private company forum at the 28th Annual Goldman Sachs Global Healthcare Conference being held June 11-June 14, 2007 at the Ritz Carlton Hotel in Dana Point, California. 

“We are very pleased to be participating in the Private Company Forum at Goldman Sachs this year,” said Keith Leonard, President and CEO. “We look forward to discussing our lead product candidate, ATX-101, an injectable adipolytic agent that we are now taking into human clinical trials.”

KYTHERA announced in January the initiation of the Company’s first human clinical trial, a Phase I/II study of ATX-101 for the reduction of localized fat deposits. ATX-101 is initially being investigated for the treatment of superficial lipomas. 

Keith Leonard, President and Chief Executive Officer and Amit Munshi, Chief Business Officer, will be available to discuss the Company during the forum.